Comparison of Two Stability-Indicating Chromatographic Methods for the Determination of Mirabegron in Presence of Its Degradation Product

dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorYehia A.M.
dc.contributor.authorSami I.
dc.contributor.authorRiad S.M.
dc.contributor.authorEl-Saharty Y.S.
dc.contributor.otherDepartment of Analytical Chemistry
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherCairo University
dc.contributor.otherKasr El-Aini Street
dc.contributor.otherCairo
dc.contributor.other11562
dc.contributor.otherEgypt; Pharmaceutical Analytical Chemistry Department
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherOctober University for Modern Sciences and Arts
dc.contributor.other6 October City
dc.contributor.other11787
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:41:27Z
dc.date.available2020-01-09T20:41:27Z
dc.date.issued2017
dc.descriptionScopus
dc.description.abstractMirabegron is a novel ?3-adrenoceptor agonist containing an amide group. It was subjected to stress conditions of acidic and alkaline hydrolyses. The hydrolytic degradation product was isolated and its structure was confirmed using mass and IR spectrometry. Two stability-indicating chromatographic methods have been proposed for the determination of mirabegron. TLC method was applied using silica gel as stationary phase and chloroform methanol ammonia (9.0:1.0:0.1 by volume) as the mobile phase, and chromatograms were scanned at 250. nm. Accurate determination of the drug was achieved over the concentration range of 2. 1. g per band. In addition, an isocratic HPLC method was developed on Agilent C18 column (150. mm. נ4.5.mm I.D., particle size 5.m) using ethanol-phosphate buffer pH 2.5 (30:70, by volume) as a mobile phase with flow rate of 1.mL.min?1.The intact drug was detected at 255.nm with running time less than 5.min. Mirabegron was determined accurately in a concentration range of 1.25.g.mL?1. The proposed chromatographic methods were applied successfully for the assay of mirabegron in pharmaceutical dosage form and both methods were validated as per the International Conference on Harmonization guidelines and statistically compared with a reported gradient HPLC method. 2016, Springer-Verlag Berlin Heidelberg.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=23963&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.1007/s10337-016-3210-1
dc.identifier.doiPubMed ID :
dc.identifier.issn95893
dc.identifier.otherhttps://doi.org/10.1007/s10337-016-3210-1
dc.identifier.otherPubMed ID :
dc.identifier.urihttps://t.ly/AXneG
dc.language.isoEnglishen_US
dc.publisherFriedr. Vieweg und Sohn Verlags GmbHen_US
dc.relation.ispartofseriesChromatographia
dc.relation.ispartofseries80
dc.subjectHigh performance liquid chromatographyen_US
dc.subjectMirabegronen_US
dc.subjectStability indicating methoden_US
dc.subjectThin layer chromatographyen_US
dc.subjectmirabegronen_US
dc.subjectsilica gelen_US
dc.subjectArticleen_US
dc.subjectcomparative studyen_US
dc.subjectdensitometryen_US
dc.subjectdrug degradationen_US
dc.subjectdrug determinationen_US
dc.subjectdrug formulationen_US
dc.subjectdrug releaseen_US
dc.subjecthigh performance liquid chromatographyen_US
dc.subjecthydrolysisen_US
dc.subjectmeasurement accuracyen_US
dc.subjectpriority journalen_US
dc.subjectthin layer chromatographyen_US
dc.titleComparison of Two Stability-Indicating Chromatographic Methods for the Determination of Mirabegron in Presence of Its Degradation Producten_US
dc.typeArticleen_US
dcterms.isReferencedByAndersson, K.E., Chapple, C.R., Current pharmacotherapy of lower urinary tract symptoms (2011) Surgery (Oxford), 29, pp. 260-264; Novara, G., Cornu, J.N., Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns (2013) Eur Urol, 63, pp. 306-308. , COI: 1:CAS:528:DC%2BC38Xhsl2ju77I; G. r. g, S., (2000) Identification and determination of impurities in drugs, , Elsevier, Amsterdam; Bhimanadhuni, C.N., Garikapati, D.R., RP HPLC method for the determination of mirabegron in pharmaceutical dosage form (2012) Am J Pharm Tech Res, 2, pp. 565-571; Rajan, N., Anverbasha, K., Development and validation of a LC method for the enantiomeric purity determination of S-mirabegron in a pharmaceutical drug substance using a amylose immobilised based chiral stationary phase (2014) Am J PharmTech Res, 4, pp. 434-441; van Teijlingen, R., Meijer, J., Takusagawa, S., van Gelderen, M., van den Beld, C., Usui, T., Development and validation of LC. MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study (2012) J Chromatogr B, 887, pp. 102-111; Kalariya, P.D., Sharma, M., Garg, P., Thota, J.R., Ragampeta, S., Talluri, M.K., Characterization of stress degradation products of mirabegron using UPLC-QTOF-MS/MS and in silico toxicity predictions of its degradation products (2015) RSC Adv, 5, pp. 31024-31038. , COI: 1:CAS:528:DC%2BC2MXlt1Ciuro%3D; Pharmacopoeia, B., Her Majesty Stationery Office (2011) London; Henry, M.B., Charles, O.L., Wait, R.L., (1963) Physical and technical pharmacy, , Mc Graw-Hill B. Co., New York; Solomons, T.W.G., Fryhle, C.B., Organic Chemistry 8th ed (2004) Organic chemistry, , Wiley, Hoboken; Hegelund, F., Larsen, R.W., Palmer, M.H., The vibrational spectrum of thiazole between 600 and 1400�cm?1 revisited: a combined high-resolution infrared and theoretical study (2007) J Mol Spectrosc, 244, pp. 63-78. , COI: 1:CAS:528:DC%2BD2sXot1Gitbg%3D; Iesce, M.R., Cermola, F., Temussi, F., Photooxygenation of heterocycles (2005) Curr Org Chem, 9, pp. 109-139. , COI: 1:CAS:528:DC%2BD2MXhslWk; Wu, L., Hong, T.Y., Vogt, F.G., Structural analysis of photo-degradation in thiazole-containing compounds by LC�MS/MS and NMR (2007) J Pharm Biomed Anal, 44, pp. 763-772. , COI: 1:CAS:528:DC%2BD2sXnslWhtrY%3D; Grinberg, N., (1990) Modern thin-layer chromatography, , Marcel Dekker Inc, New York; Sadek, P.C., (1996) The HPLC solvent guide, , Wiley, New York; Sheldon, R.A., Fundamentals of green chemistry: efficiency in reaction design (2012) Chem Soc Rev, 41, pp. 1437-1451. , COI: 1:CAS:528:DC%2BC38XhsVajs70%3D; United States Pharmacopeial Inc, , United States Pharmacopoeia (2004); Ga?uszka, A., Migaszewski, Z.M., Konieczka, P., Namie?nik, J., Analytical Eco-Scale for assessing the greenness of analytical procedures (2012) TrAC Trends Anal Chem, 37, pp. 61-72; Guideline, I.H., Validation of analytical procedures: text and methodology (2005) Q2 (R1)
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
avatar_scholar_128.png
Size:
2.73 KB
Format:
Portable Network Graphics
Description:
Loading...
Thumbnail Image
Name:
Yehia2017_Article_ComparisonOfTwoStability-Indic.pdf
Size:
733.59 KB
Format:
Adobe Portable Document Format
Description: